Factbox-Global drugmakers invest billions to boost US presence

June 15 (Reuters) - Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capableness and probe successful the country.

Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche person announced astir $500 cardinal successful U.S. investments arsenic they question to fortify infrastructure, mitigate supply-chain risks and reassure investors.

Pfizer

Pfizer reached a woody with President Donald Trump connected September 30 to put $70 cardinal successful probe and improvement and home manufacturing, and received a three-year ‌grace play exempting its products from the pharmaceutical-targeted tariffs.

GSK

The London-based drugmaker plans to put $30 cardinal successful U.S. probe and improvement and proviso concatenation infrastructure implicit 5 years.

Eli Lilly

U.S. President Donald Trump said successful January that Eli Lilly plans to physique ‌six plants successful the United States.

Lilly said past twelvemonth that it planned to walk astatine slightest $27 cardinal to physique 4 U.S. plants to grow accumulation and bolster aesculapian proviso chains. The institution has since announced details connected 3 plants, successful Alabama, Virginia and Texas.

Lilly successful January said it volition physique a $3.5 cardinal pharmaceutical manufacturing installation successful ​Pennsylvania, its 4th caller site, successful an effort to grow U.S. accumulation and bolster aesculapian proviso chains.

Johnson & Johnson

The drugmaker plans to rise U.S. investments by 25%, totaling $55 billion, implicit the adjacent 4 years. It plans to physique 4 plants, including 1 astatine Wilson, North Carolina, and different astatine Tokyo-based Fujifilm Biotechnologies' manufacturing tract successful Holly Springs, North Carolina, implicit the adjacent 10 years.

The institution said successful June it has invested astir $1 cardinal successful Jacksonville, Florida, to fortify U.S.-based manufacturing for its oculus attraction business. The caller installation is expected to beryllium afloat operational successful 2028, J&J said.

Roche

The Swiss drugmaker said successful April past twelvemonth it would put $50 cardinal successful the U.S. implicit the adjacent 5 years.

A period later, it announced an further $550 cardinal concern to grow its Indianapolis diagnostics manufacturing hub. The enlargement volition span Indiana, Pennsylvania, Massachusetts, and California, creating much than 12,000 jobs.

In January, ‌Roche said it volition much than treble its concern successful its cause manufacturing installation successful ⁠Holly Springs, North Carolina, to astir $2 billion, up from the implicit $700 cardinal announced successful May 2025.

AstraZeneca

The Anglo-Swedish drugmaker volition put $50 cardinal connected U.S. manufacturing by 2030. The concern volition money a caller cause substance installation successful Virginia, its largest single-site planetary investment, alongside expansions successful Maryland, Massachusetts, California, Indiana and Texas.